Freeline Therapeutics Holdings plc announced that Mark Baldry, MBA, has been appointed as the Company’s new Chief Commercial Officer, effective November 2, 2020. Mark is an experienced commercial leader with a 30-year track record in positions of increasing responsibility at leading biopharmaceutical companies in marketing, sales and public affairs roles across Europe, Canada and the US. He has predominately worked across rare and specialty disease areas, where he has championed multiple commercial launches. Mark joins Freeline from Wave Life Sciences where he served as Chief Commercial Officer and prior to that as Senior Vice President, Global Marketing & Commercial Operations at Amicus Therapeutics. In these roles, he was responsible for building global commercial strategies to support launches of innovative medicines in orphan diseases, including the first oral chaperone therapy for the treatment of Fabry disease. Prior to that, Mark held multiple leadership positions at Biogen, including Vice President, Public Affairs and Vice President, New Product Commercialisation. He also held leadership roles at the Human Genetic Therapies division of Shire including Head of Global Strategic Marketing and Head of Marketing, Market Access and Public Affairs, Europe, Middle East and Africa.